GenVec (NASDAQ: GNVC) is one of 188 publicly-traded companies in the “Biotechnology & Medical Research” industry, but how does it compare to its peers? We will compare GenVec to related businesses based on the strength of its institutional ownership, analyst recommendations, profitability, valuation, risk, dividends and earnings.
This table compares GenVec and its peers’ net margins, return on equity and return on assets.
||Return on Equity
||Return on Assets
Earnings & Valuation
This table compares GenVec and its peers gross revenue, earnings per share and valuation.
GenVec’s peers have higher revenue, but lower earnings than GenVec. GenVec is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.
This is a summary of current recommendations for GenVec and its peers, as reported by MarketBeat.com.
||Strong Buy Ratings
GenVec currently has a consensus target price of $7.00, suggesting a potential downside of 2.64%. As a group, “Biotechnology & Medical Research” companies have a potential upside of 13.39%. Given GenVec’s peers stronger consensus rating and higher possible upside, analysts plainly believe GenVec has less favorable growth aspects than its peers.
Insider and Institutional Ownership
6.2% of GenVec shares are owned by institutional investors. Comparatively, 49.5% of shares of all “Biotechnology & Medical Research” companies are owned by institutional investors. 8.1% of GenVec shares are owned by company insiders. Comparatively, 14.8% of shares of all “Biotechnology & Medical Research” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
GenVec peers beat GenVec on 9 of the 11 factors compared.
GenVec Company Profile
GenVec, Inc. (GenVec) is a clinical-stage biopharmaceutical company, engaged in the development of therapeutics and vaccines. The Company designs, tests and manufactures adenoviral-based product candidates. The Company’s development programs address therapeutic areas, such as hearing loss and balance disorders, as well as vaccines against infectious diseases, including respiratory syncytial virus (RSV), herpes simplex virus (HSV), Enterovirus D68 (EV-D68) and malaria. In the area of animal health, it is developing vaccines against foot-and-mouth disease (FMD). The Company develops and commercializes its product candidates through collaborations. The Company’s lead product candidate is CGF166. The Company’s vaccine candidates include preventative vaccines against RSV and malaria, and a therapeutic vaccine for HSV. The Company is developing vaccine and anti-viral candidates for the prevention and containment of FMD outbreaks.
Receive News & Ratings for GenVec Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GenVec and related companies with MarketBeat.com's FREE daily email newsletter.